AEterna Zentaris: Expecting Good News? - trackseekingalpha

Sign Up | Log In | What is SocialPicks?

AEterna Zentaris: Expecting Good News?
Aug 02, 2009 09:57 AM UTC

trackseekingalpha

Return	Risk
-13.40%	HIGH

Tracked Blogger

Profile & Performance

Subscribe to author

Symbol	Sentiment	Start	Return	Closed
AEZS	n/a

Via Long Investment Ideas from Seeking Alpha:

AEterna Zentaris (AEZS) is a speculative biopharmaceutical company that demonstrates why it is always best to choose speculative biotech / pharma plays that have multiple drug candidates in the pipeline and are not 'one trick ponies.'

When the company announced that its lung cancer drug, Perifosine, failed to prove effective in a mid-stage trial, the stock plummeted to under thirty cents. However, because the company had more to offer than just Perifosine, the stock quickly recovered and closed the week at $2.62.

Read the rest of original post »

Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment

IN THE PRESS

None of the information contained on SocialPicks.com constitutes a recommendation by SocialPicks or its users that any particular security, portfolio of securities, transaction, or investment strategy is suitable for any specific person. SocialPicks is not responsible for the posts, discussions, and recommendations of the users on the Site. SocialPicks does not provide investment advice. You must make your own independent decisions regarding any security, portfolio of securities, transaction, or investment strategy mentioned on the website. SocialPicks' users' past results are not necessarily indicative of future performance. Neither SocialPicks nor any of its users guarantees any specific outcome or profit, and you should be aware of the real risk of loss in following any strategy or investments discussed on the website. You understand and agree that you use the Site and Services at your own discretion and risk and that you will be solely responsible for any damages that arise from such use. Before acting on any information contained on the website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.